"Heyan Biotech mainly provides drug discovery services such as drug activity screening and kinase function test and it has established close research collaborations with many innovative drug companies, well-known universities and scientific research institutes,” said Song Li, chairman and CEO of Frontage. “Its technology platforms as well as talents could effectively complement the existing service lines of Frontage.”
Heyan Biotech will focus on expanding the application of SPR technology, Protac technology, ion channels, GPCR targets, intracellular kinase binding evaluation and high connotation technology detection platform. It will cover the fields of neuropathy, metabolic diseases, inflammation, cancer and safety evaluation targets. In addition, Heyan Biotech will expand its service capacity in drug discovery to enhance Frontage's one-stop service capacity and capability in the field of drug discovery and development.